|Thursday, October 13, 2022|
|12:00 PM - 01:00 PM ET|
The two recent executive orders by President Joseph Biden present both opportunities and challenges to the US life sciences and biotechnology industries. One calls for sustainability and advancement in biotechnology and biomanufacturing and is viewed as a first step toward identifying areas of regulatory ambiguity—which impedes investment and innovation. The other clarified and elaborated key US industries and business sectors that could anticipate increased regulatory scrutiny from the Committee on Foreign Investment in the United States (CFIUS) when evaluating M&A transactions.
Join us for a panel discussion featuring partner Kathleen Sanzo, leader of the firm’s FDA and healthcare practice and co-chair of the firm’s life sciences industry team; partner Carl Valenstein, member of our CFIUS Working Group; and partner Suzanne Filippi as moderator as they discuss the aspects of the two recent executive orders; impact on investment, funding, partnering transactions, and M&A; and what biotech companies need to know when engaging in future business matters.
Questions? Please contact AJ Dowers.